Skip to main content
SpringerLink
Log in

Sunitinib in the Treatment of Advanced Solid Tumors

  • Chapter
  • First Online:
Small Molecules in Oncology

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 201))

Abstract

Sunitinib is an oral multikinase inhibitor that blocks the vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) alpha and beta, c-kit, and other receptors. These attributes have proven to be efficacious in the treatment of metastatic renal cell carcinoma (RCC), unresectable gastrointestinal stromal tumors (GIST), and well-differentiated advanced pancreatic neuroendocrine tumors (PNET). Though activity has been reported in other tumor types, phase III trials have not yet demonstrated improved survival outcomes in these cancers. Most side effects including hypertension, hand-foot syndrome, and diarrhea are generally well manageable. This review will detail the preclinical data leading up to the results of the pivotal phase III clinical trials that have led to the widespread use of sunitinib in advanced RCC, GIST, and PNET.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma. http://clinicaltrials.gov/ct2/show/NCT00326898

  • Azizi M, Chedid A, Oudard S (2008) Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med 358:95–97

    Article  CAS  PubMed  Google Scholar 

  • Banks RE, Tirukonda P, Taylor C et al (2006) Genetic and epigenetic analysis of von Hippel–Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 66:2000–2011

    Article  CAS  PubMed  Google Scholar 

  • Barrios CH, Liu MC, Lee SC et al (2010) Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 121:121–131

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Bergh J, Bondarenko IM, Lichinitser MR et al (2012) First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol 30:921–929

    Article  CAS  PubMed  Google Scholar 

  • Biagi JJ, Oza AM, Grimshaw R et al (2008) A phase II study of sunitinib (SU11248) in patients (pts) with recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma—NCIC CTG IND 185. J Clin Oncol 26:5522

    Google Scholar 

  • Blanke CD, Rankin C, Demetri GD et al (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626–632

    Article  CAS  PubMed  Google Scholar 

  • Brauch H, Weirich G, Brieger J et al (2000) VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res 60:1942–1948

    CAS  PubMed  Google Scholar 

  • Bukowski RM, Kabbinavar FF, Figlin RA et al (2007) Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 25:4536–4541

    Article  CAS  PubMed  Google Scholar 

  • Burstein HJ, Elias AD, Rugo HS et al (2008) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26:1810–1816

    Article  CAS  PubMed  Google Scholar 

  • Carr LL, Mankoff DA, Goulart BH et al (2010) Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 16:5260–5268

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Carrato A, Swieboda-Sadlej A, Staszewska-Skurczynska M et al (2013) Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. J Clin Oncol 31:1341–1347

    Article  CAS  PubMed  Google Scholar 

  • Casanovas O, Hicklin DJ, Bergers G et al (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8:299–309

    Article  CAS  PubMed  Google Scholar 

  • Chaudhry A, Papanicolaou V, Oberg K et al (1992) Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system. Cancer Res 52:1006–1012

    CAS  PubMed  Google Scholar 

  • Choueiri TK, Plantade A, Elson P et al (2008) Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 26:127–131

    Article  CAS  PubMed  Google Scholar 

  • Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884–896

    Article  CAS  PubMed  Google Scholar 

  • Christensen JG (2007) A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Oncol 18(Suppl 10):x3–x10

    Article  PubMed  Google Scholar 

  • Clifford SC, Prowse AH, Affara NA et al (1998) Inactivation of the von Hippel–Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 22:200–209

    Article  CAS  PubMed  Google Scholar 

  • Cohen HT, McGovern FJ (2005) Renal-cell carcinoma. N Engl J Med 353:2477–2490

    Article  CAS  PubMed  Google Scholar 

  • Cohen EE, Needles BM, Cullen KJ et al (2008) Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol 26(suppl; abstract 6025)

    Google Scholar 

  • Cooney MM, Garcia J, Brell J et al (2007) A phase I study of bevacizumab in combination with sunitinib in advanced solid tumors. J Clin Oncol 25:15532

    Google Scholar 

  • Coppin C, Porzsolt F, Awa A et al (2005) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev (1):CD001425

    Google Scholar 

  • Coppin C, Le L, Porzsolt F et al (2008) Targeted therapy for advanced renal cell carcinoma. Cochrane Database Syst Rev (2):CD006017

    Google Scholar 

  • Corless CL, Fletcher JA, Heinrich MC (2004) Biology of gastrointestinal stromal tumors. J Clin Oncol 22:3813–3825

    Article  CAS  PubMed  Google Scholar 

  • Davis MP, Goldstein D, George S et al (2011) Asthenia and fatigue as predictors of sunitinib efficacy in gastrointestinal stromal tumour (GIST). Eur J Cancer 47(suppl; abstract 1140)

    Google Scholar 

  • Dematteo RP, Gold JS, Saran L et al (2008) Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 112:608–615

    Article  PubMed  Google Scholar 

  • Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472–480

    Article  CAS  PubMed  Google Scholar 

  • Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329–1338

    Article  CAS  PubMed  Google Scholar 

  • DePrimo SE, Huang X, Blackstein ME et al (2009) Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure. Clin Cancer Res 15:5869–5877

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Donskov F, Cams A, Barrios CH et al (2011a) Neutropenia and thrombocytopenia during treatment as biomarkers of sunitinib efficacy in patients with metastatic renal cell carcinoma (mRCC). Eur J Cancer 47(suppl; abstract 1141)

    Google Scholar 

  • Donskov F, von Mehren M, Cams A et al (2011b) Neutropenia as a biomarker of sunitinib efficacy in patients (Pts) with gastrointestinal stromal tumour (GIST). Eur J Cancer 47(suppl; abstract 1138)

    Google Scholar 

  • Donskov F, Michaelson MD, Puzanov I et al (2012) Comparative assessment of sunitinib-associated adverse events as potential biomarkers of efficacy in metastatic renal cell carcinoma (mRCC). Ann Oncol 23(suppl; abstract 785O)

    Google Scholar 

  • Ehehalt F, Saeger HD, Schmidt CM et al (2009) Neuroendocrine tumors of the pancreas. Oncologist 14:456–467

    Article  CAS  PubMed  Google Scholar 

  • Faivre S, Delbaldo C, Vera K et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25–35

    Article  CAS  PubMed  Google Scholar 

  • Feldman DR, Kondagunta GV, Ronnen EA et al (2007) Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 25:5099

    Google Scholar 

  • Figlin RA, Hutson TE, Tomczak P et al (2008) Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol 26:5024

    Google Scholar 

  • Fjällskog ML, Lejonklou MH, Oberg KE et al (2003) Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 9:1469–1473

    PubMed  Google Scholar 

  • Fjällskog ML, Hessman O, Eriksson B et al (2007) Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas. Acta Oncol 46:741–746

    Article  PubMed  Google Scholar 

  • Foster K, Prowse A, van den Berg A et al (1994) Somatic mutations of the von Hippel–Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet 3:2169–2173

    Article  CAS  PubMed  Google Scholar 

  • Garcia-Donas J, Esteban E, Leandro-García LJ et al (2011) Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol 12:1143–1150

    Article  CAS  PubMed  Google Scholar 

  • George S, Blay JY, Casali PG et al (2008) Continuous daily dosing (CDD) of sunitinib (SU) in pts with advanced GIST: updated efficacy, safety, PK and pharmacodynamic analysis. J Clin Oncol 26:10554

    Google Scholar 

  • George S, Merriam P, Maki RG et al (2009) Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 27:3154–3160

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • George S, Reichardt P, Lechner T et al (2012) Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib. Ann Oncol 23:3180–3187

    Article  CAS  PubMed  Google Scholar 

  • Gnarra JR, Tory K, Weng Y et al (1994) Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7:85–90

    Article  CAS  PubMed  Google Scholar 

  • Goodman VL, Rock EP, Dagher R et al (2007) Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 13:1367–1373

    Article  CAS  PubMed  Google Scholar 

  • Gore ME, Porta C, Oudard S et al (2007) Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J Clin Oncol 25:5010

    Google Scholar 

  • Halfdanarson TR, Rabe KG, Rubin J et al (2008) Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 19:1727–1733

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Hansel DE, Rahman A, Hermans J et al (2003) Liver metastases arising from well-differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression. Mod Pathol 16:652–659

    Article  PubMed  Google Scholar 

  • Heinrich MC, Corless CL, Demetri GD et al (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342–4349

    Article  CAS  PubMed  Google Scholar 

  • Heinrich MC, Maki RG, Corless CL et al (2008) Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 26:5352–5359

    Google Scholar 

  • Heng DY, Bukowski RM (2007) Renal cell carcinoma: evolving approaches to advanced non-clear cell carcinoma. Oncol Rev 1:170–176

    Google Scholar 

  • Houk B, Garrett M, Bello C (2005) Population pharmacokinetics of SU011248 and its primary metabolite SU12662 in oncology patients and healthy volunteers. In: Presented at the EORTC/AACR/NCI molecular targets meeting, Philadelphia, PA, 14–18 Nov 2005

    Google Scholar 

  • Houk BE, Bello CL, Michaelson MD et al (2007) Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): a population pharmacokinetic/pharmacodynamic (PKPD) approach. J Clin Oncol 25:5027

    Google Scholar 

  • Inoue M, Hager JH, Ferrara N et al (2002) VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 1:193–202

    Article  CAS  PubMed  Google Scholar 

  • Je Y, Schutz FA, Choueiri TK (2009) Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 10:967–974

    Article  CAS  PubMed  Google Scholar 

  • Kenck C, Wilhelm M, Bugert P et al (1996) Mutation of the VHL gene is associated exclusively with the development of non-papillary renal cell carcinomas. J Pathol 179:157–161

    Article  CAS  PubMed  Google Scholar 

  • Klimstra DS, Arnold R, Capella C et al (2010) Neuroendocrine neoplasms of the pancreas. WHO classification of tumours of the digestive system, pp 322–326

    Google Scholar 

  • Kollmannsberger C, Heng DY, Murray N et al (2007a) A population-based study evaluating metastatic renal cell cancer (mRCC) patients treated with interferon (IFN) alone, first-line IFN then second-line sunitinib, or sunitinib alone. J Clin Oncol 25:15572

    Google Scholar 

  • Kollmannsberger C, Soulieres D, Wong R et al (2007b) Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J 1:S41–S54

    CAS  PubMed Central  PubMed  Google Scholar 

  • Kondo K, Yao M, Yoshida M et al (2002) Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer 34:58–68

    Article  CAS  PubMed  Google Scholar 

  • Kovacs G, Akhtar M, Beckwith BJ et al (1997) The Heidelberg classification of renal cell tumours. J Pathol 183:131–133

    Article  CAS  PubMed  Google Scholar 

  • Kulke MH, Lenz HJ, Meropol NJ et al (2008) Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26:3403–3410

    Article  CAS  PubMed  Google Scholar 

  • La Rosa S, Uccella S, Finzi G et al (2003) Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. Hum Pathol 34:18–27

    Article  PubMed  Google Scholar 

  • Laird AD, Vajkoczy P, Shawver LK et al (2000) SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 60:4152–4160

    CAS  PubMed  Google Scholar 

  • Maki RG, Fletcher JA, Heinrich MC et al (2005) Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol 23:9011

    Google Scholar 

  • Mansour JC, Chen H (2004) Pancreatic endocrine tumors. J Surg Res 120:139–161

    Article  CAS  PubMed  Google Scholar 

  • McDermott DF, Regan MM, Clark JI et al (2005) Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23:133–141

    Article  CAS  PubMed  Google Scholar 

  • Mendel DB, Laird AD, Xin X et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327–337

    CAS  PubMed  Google Scholar 

  • Modlin IM, Oberg K, Chung DC et al (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9:61–72

    Article  CAS  PubMed  Google Scholar 

  • Motzer RJ, Bacik J, Murphy BA et al (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289–296

    Article  CAS  PubMed  Google Scholar 

  • Motzer RJ, Michaelson MD, Redman BG et al (2006a) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16–24

    Article  CAS  PubMed  Google Scholar 

  • Motzer RJ, Rini BI, Bukowski RM et al (2006b) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516–2524

    Article  CAS  PubMed  Google Scholar 

  • Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124

    Article  CAS  PubMed  Google Scholar 

  • Negrier S, Escudier B, Lasset C et al (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe francais d’immunotherapie. N Engl J Med 338:1272–1278

    Article  CAS  PubMed  Google Scholar 

  • Negrier S, Perol D, Ravaud A et al (2007) Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 110:2468–2477

    Article  CAS  PubMed  Google Scholar 

  • Nowain A, Bhakta H, Pais S et al (2005) Gastrointestinal stromal tumors: clinical profile, pathogenesis, treatment strategies and prognosis. J Gastroenterol Hepatol 20:818–824

    Article  PubMed  Google Scholar 

  • Randomized study of sunitinib plus FOLFOX versus bevacizumab plus FOLFOX in metastatic colorectal cancer. http://clinicaltrials.gov/show/NCT00609622

  • Ravaud A, de la Fouchardière C, Asselineau J et al (2010) Efficacy of sunitinib in advanced medullary thyroid carcinoma: intermediate results of phase II THYSU. Oncologist 15:212–213

    Article  PubMed Central  PubMed  Google Scholar 

  • Raymond E, Dahan L, Raoul JL et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501–513

    Article  CAS  PubMed  Google Scholar 

  • Richards CJ, Je Y, Schutz FA et al (2011) Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. J Clin Oncol 29:3450–3456

    Article  CAS  PubMed  Google Scholar 

  • Rini BI, Small EJ (2005) Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23:1028–1043

    Article  CAS  PubMed  Google Scholar 

  • Rini BI, Tamaskar I, Shaheen P et al (2007) Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99:81–83

    Article  CAS  PubMed  Google Scholar 

  • Rini BI, Choueiri TK, Elson P et al (2008) Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. Cancer 113:1309–1314

    Article  CAS  PubMed  Google Scholar 

  • Rini BI, Cohen DP, Lu DR et al (2011) Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103:763–773

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Robert NJ, Saleh MN, Paul D et al (2011) Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. Clin Breast Cancer 11:82–92

    Article  CAS  PubMed  Google Scholar 

  • Scagliotti GV, Krzakowski M, Szczesna A et al (2012) Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol 30:2070–2078

    Article  CAS  PubMed  Google Scholar 

  • Schmidinger M, Vogl UM, Bojic M et al (2011) Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer 117:534–544

    Article  PubMed  Google Scholar 

  • Shuin T, Kondo K, Torigoe S et al (1994) Frequent somatic mutations and loss of heterozygosity of the von Hippel–Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 54:2852–2855

    CAS  PubMed  Google Scholar 

  • Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30

    Article  PubMed  Google Scholar 

  • Sun L, Liang C, Shirazian S et al (2003) Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 46:1116–1119

    Article  CAS  PubMed  Google Scholar 

  • Sunitinib malate as maintenance therapy in treating patients with Stage III or Stage IV non-small cell lung cancer previously treated with combination chemotherapy. http://clinicaltrials.gov/show/NCT00693992

  • Terris B, Scoazec JY, Rubbia L et al (1998) Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 32:133–138

    Article  CAS  PubMed  Google Scholar 

  • Van Glabbeke M, Verweij J, Casali PG et al (2005) Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer–Italian Sarcoma Group–Australasian Gastrointestinal Trials Group study. J Clin Oncol 23:5795–5804

    Article  PubMed  Google Scholar 

  • Verweij J, Casali PG, Zalcberg J et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364:1127–1134

    Article  CAS  PubMed  Google Scholar 

  • Vinik A, Van Cutsem E, Niccoli P et al (2012) Updated results from a phase III trial of sunitinib versus placebo in patients with progressive, unresectable, well-differentiated pancreatic neuroendocrine tumor (NET). J Clin Oncol 30(suppl; abstract 4118)

    Google Scholar 

  • Weisberg E, Griffin JD (2003) Resistance to imatinib (Glivec): update on clinical mechanisms. Drug Resist Updat 6:231–238

    Article  CAS  PubMed  Google Scholar 

  • Witteles RM, Telli ML, Fisher GA et al (2008) Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. J Clin Oncol 26:9597

    Article  Google Scholar 

  • Wolter P, Stefan C, Decallonne B et al (2008) The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer 99:448–454

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Wong E, Rosen LS, Mulay M et al (2007) Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 17:351–355

    Article  CAS  PubMed  Google Scholar 

  • Wulbrand U, Wied M, Zöfel P et al (1998) Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours. Eur J Clin Invest 28:1038–1049

    Article  CAS  PubMed  Google Scholar 

  • Yang JC, Sherry RM, Steinberg SM et al (2003) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21:3127–3132

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514–523

    Article  CAS  PubMed  Google Scholar 

  • Yuasa T, Takahashi S, Hatake K et al (2011) Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer. Cancer Sci 102:1949–1957

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology, Tom Baker Cancer Center, Calgary, Canada

    Amal Imbulgoda & Daniel Y. C. Heng

  2. Medical Oncology, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada

    Christian Kollmannsberger

Authors
  1. Amal Imbulgoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel Y. C. Heng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christian Kollmannsberger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Kollmannsberger .

Editor information

Editors and Affiliations

  1. Cancer Center Heilbronn-Franken, SLK-Kliniken Heilbronn GmbH Medizinische Klinik III, Heilbronn, Germany

    Uwe M. Martens

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Imbulgoda, A., Heng, D.Y.C., Kollmannsberger, C. (2014). Sunitinib in the Treatment of Advanced Solid Tumors. In: Martens, U. (eds) Small Molecules in Oncology. Recent Results in Cancer Research, vol 201. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54490-3_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-54490-3_9

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-54489-7

  • Online ISBN: 978-3-642-54490-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation